# Origin -- Peter Thiel Evaluation

The first question I ask is always the same: what is the secret? What does Origin know about the world that most intelligent people actively disagree with? And here I struggle to find one. The thesis -- that generative AI can design superior synthetic regulatory DNA elements for gene therapy -- is not a contrarian insight. It is the consensus view of the computational genomics establishment circa 2026. Google DeepMind built AlphaGenome. Nature Genetics published a paper in 2025 on this exact application. Asimov has raised over $205 million and already offers tissue-specific promoter design. Academic labs at the Broad Institute and elsewhere are producing open-source tools that do similar work. When your company's core thesis is shared by DeepMind, multiple nine-figure startups, and the leading journals in your field, you do not have a secret. You have a consensus dressed in startup language. And consensus in a crowded market means one thing: competition. The structural dynamics here are clear -- multiple well-funded players converging on the same molecular target, each claiming slightly better performance on the same benchmarks. This is mimetic convergence, not monopoly creation.

The competitive landscape is particularly concerning. Asimov, with twenty-five times Origin's likely capital, already designs tissue-specific promoters as part of a broader genetic circuit platform. They have established pharma relationships and the resources to deepen their regulatory DNA capabilities whenever they choose. Dyno Therapeutics has $109 million and Roche partnership revenue. Tessera has over half a billion dollars. Origin enters this space as a four-person pre-seed team claiming to outperform AlphaGenome on a benchmark that has not been independently verified. Even if the performance claim is true today, the question is durability: how long does a computational advantage hold against DeepMind's resources, Asimov's validation infrastructure, and an academic community publishing its breakthroughs openly? The answer in machine learning is typically months, not years. A claimed benchmark lead at pre-seed is not a moat -- it is a snapshot.

The founding team presents a mixed signal. Two CS undergraduates from UIUC with ML research backgrounds -- technically capable, but thin on the domain conviction I look for. Yash Rathod's prior exit was Diginoor, described as India's first NFT marketplace. An NFT marketplace in 2021-2022 is precisely the kind of mimetic, trend-chasing venture that signals indefinite thinking -- following the herd into whatever category is hot, not building from a deep conviction about how the world should work. Malhar Bhide has more relevant biology exposure, including a Nature Scientific Reports publication and work at Wadhwani AI on healthcare ML, but the dossier describes this as high school research, and his most recent engineering experience was at Automorphic, a YC S23 company in a different domain entirely. The advisory board -- Kellis at MIT, Paulk at UCSF, Bashir at UIUC -- provides credibility, but advisors are decorative unless the founders themselves have the deep biological intuition to know which regulatory sequences matter and why. When I backed Alex Karp at Palantir, his doctorate in social theory was unconventional but his understanding of intelligence problems was genuinely deep. I do not see equivalent domain depth here.

The strongest bull case would require believing several things simultaneously: that Origin's Axis model maintains its claimed performance advantage as DeepMind and academic groups iterate; that the proprietary dataset of validated synthetic sequences achieves sufficient scale before competitors assemble equivalent data; that pharma companies choose to partner with a four-person pre-seed startup rather than Asimov, internal teams, or academic collaborators; and that the regulatory element layer specifically -- not capsids, not full genetic circuits, not genome writing -- emerges as the decisive bottleneck in gene therapy commercialization. If all of these are true, Origin could build a genuine data flywheel where each partnership generates validated sequences that improve the model, widening the performance gap and making the dataset increasingly indispensable. The gene therapy market's 19.6% CAGR and the specialization gap -- most pharma R&D organizations lack the ML expertise to build this internally -- support the market timing. This is a plausible path, but it requires too many simultaneous conditions to hold, and the absence of any validated wet-lab data means we are entirely in the realm of computational promises.

The go-to-market language confirms my concern about indefinite thinking. "Seeking partnerships with pharma/biotech companies" is not a plan -- it is a process. Which pharma company? Which therapeutic program? Which disease, which cell type, which specific regulatory challenge will Origin solve first to demonstrate that their synthetic elements work in living systems? The absence of a defined beachhead -- a single partnership, a specific disease indication, a named customer -- means Origin is approaching a massive, complex market without the narrow focus that monopoly requires. When PayPal started, we did not target "all payments." We targeted eBay power sellers -- a small, desperate, reachable audience for whom our product was transformatively better. I see no equivalent specificity here.

The fundamental problem is that Origin is entering a category, not creating one. The regulatory DNA design space is an emerging field with multiple well-capitalized participants sharing the same thesis about the same technology applied to the same customer base. This is the structure I have spent my career avoiding. The company has competent founders, a credible advisory board, and a claim of benchmark superiority -- but no secret, no monopoly path, and no evidence of the kind of definite conviction that distinguishes founders who build enduring companies from founders who build features that get absorbed by larger platforms.

### Dimension Scores

| Criterion | Score |
|-----------|-------|
| Contrarian Secret and Monopoly Potential | 8/35 |
| Founder Conviction and Definite Vision | 8/25 |
| Technological Discontinuity and 10x Superiority | 9/20 |
| Durability and Last-Mover Defensibility | 4/10 |
| Small-Market Dominance with Expansion Path | 5/10 |
| **Total** | **34/100** |

**Total Score: 34/100** (Pass)
